EMEA and FDA Team Up on GCP

O'^Donnell, Peter
September 2009
Applied Clinical Trials;Sep2009, Vol. 18 Issue 9, p24
Academic Journal
The article focuses on the partnership between the European Medicines Agency (EMEA) and the U.S. Food and Drug Administration (FDA) to launch joint initiative to collaborate on international Good Clinical Practice (GCP) inspection activities. It mentions that EMEA and FDA will share information on inspection planning, policy and results, and conduct collaborative inspections. It notes that the initiative will aid protect clinical trial topics in the increasing globalized clinical research.


Related Articles

  • ePRO vs. Paper. José, Nadina C.; Langel, Kai // Applied Clinical Trials;Jun2010, Vol. 19 Issue 6, p68 

    The article discusses the benefits of the electronic patient reporting (ePRO) than the paper-based diaries for clinical research sponsors as accepted by Food and Drug Administration (FDA) and European Medicines Agency (EMA). The author says that the ePRO technology can cut costs through...

  • FDA Compliance Priorities and Evolution. Mathieu, Mark P. // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p48 

    Presents an updated reference guide to the U.S. Food and Drug Administration's (FDA) good clinical practice (GCP) compliance priorities. Existing and emerging FDA priorities for bioresearch monitoring program and GCP compliance; Implications that the pharmaceutical industry's relocation of...

  • A Declaration of Action. Rucker, David; Parno, Jeff // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p62 

    Considers the implications of the U.S. Food and Drug Administration's (FDA) Critical Path Initiative for medical products development for the clinical research industry in the United States. Findings of the March 2004 FDA report "Challenge and Opportunity on the Critical Path to New Medical...

  • Driving Clinical Trial Innovation. Xiao-Wei Zhu // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p66 

    Discusses the potential of the U.S. Food and Drug Administration's Critical Path Initiative to drive clinical trial innovation in the United States. Slowdown in the rate of promising medications and treatments actually reaching patients; Initiative's encouragement of cooperation between...

  • Forgotten Voices in the Transparency Debate. Getz, Kenneth A. // Applied Clinical Trials;Apr2006, Vol. 15 Issue 4, p42 

    The article comments on the debate concerning improving transparency in online clinical trials in the U.S. in 2006. At the heart of the debate is the need to decide whether a single central online registry or many different online locations can best serve the Food and Drug Administration's...

  • FDA inks draft guidance for risk-based trial monitoring.  // Medical Device Daily;8/30/2011, Vol. 15 Issue 165, p1 

    The article focuses on a draft guidance for clinical trial monitoring that has been issued by the U.S. Food and Drug Administration (FDA). Noted is the aim of the agency to promote the increased use of centralized monitoring methods. The FDA comments on a guidance from the International...

  • Pressure Grows for More Inclusive Clinical Trials. Wechsler, Jill // Applied Clinical Trials;Apr/May2014, Vol. 23 Issue 4/5, p10 

    The article discusses the growing pressure for more inclusive clinical trials. The author talks about the call for biomedical studies to fully examine how new drugs and medical products affect a broad spectrum of patient populations. She tackles a report from the U.S. Food and Drug...

  • The New Road of Cardio-Oncology in Clinical Development. Herron, David S. // Applied Clinical Trials;Apr/May2014, Vol. 23 Issue 4/5, p38 

    The article discusses the developments in cardoi-oncology in clinical development. The author provides an overview about the clinical discipline, cardio-oncology, which aims to bridge the gap between cardiology and oncology and promote safer drugs and better outcomes for cancer patients. Also...

  • Three-Pronged Approach to Optimizing Trial Monitoring. Mitchel, Jules T.; Cho, Timothy; Gittleman, Dean A.; Schloss Markowitz, Judith M.; Yong Joong Kim; Joonhyuk Choi; Hamrell, Michael R.; Nora, Sergio Dalla; Carrara, Dario // Applied Clinical Trials;Jun/Jul2014, Vol. 23 Issue 6/7, p37 

    The article discusses the three-pronged approach to optimize trial monitoring. The author talks about the publication of varied practices of monitoring clinical trials by the Clinical Trials Transformation Initiative (CTTI), a public-private partnership formally established in 2008 by the U.S....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics